

## INVITATION

Egis Pharmaceuticals Public Limited Company (the 'Company', headquarters: H-1106 Budapest, Keresztúri út 30-38.)

invites shareholders to attend the Annual General Meeting of Shareholders

to be held on January 30, 2013 at 2 p.m.

in the conference hall of Marriott Courtyard Budapest City Center (address: 1088 Budapest, József krt. 5.)

## Agenda:

- 1. Consolidated business report on the performance of the Egis Group in 2011/2012 in accordance with International Financial Reporting Standards (IFRS)
- 2. Supervisory Board's opinion on the consolidated report prepared in accordance with IFRS
- 3. Auditor's opinion on the consolidated report prepared in accordance with IFRS
- 4. Audit Committee's opinion on the consolidated report prepared in accordance with IFRS

-----

- 5. Business report on the performance of Egis Pharmaceuticals PLC in 2011/2012 in accordance with Hungarian Accounting Law (HAL)
- 6. Proposal of the Board of Directors for determination and appropriation of the 2011/2012 profit
- 7. Supervisory Board's opinion on the report prepared in accordance with HAL
- 8. Auditor's opinion on the report prepared in accordance with HAL
- 9. Audit Committee's opinion on the report prepared in accordance with HAL
- 10. Business report on the performance of Egis Pharmaceuticals PLC in 2011/2012 (IFRS)
- 11. Supervisory Board's opinion on the report (IFRS)
- 12. Auditor's opinion on the report (IFRS)

\_\_\_\_\_

13. Audit Committee's opinion on the report (IFRS)

-----



- 14. Resignation of one member of the Board of Directors and election of a new member to the Board of Directors
- 15. Election of the members of the Supervisory Board
- 16. Election of the members of the Audit Committee
- 17. Determination of the officials' remuneration for 2012/2013
- 18. Election of the Auditor for 2012/2013 and determination of its remuneration
- 19. Report on corporate governance
- 20. Proposal for the withdrawal of the resolution of the General Meeting regarding the bylaws on exercising of employer's right
- 21. Proposal for the amendment to the Articles of Association of Egis Pharmaceuticals PLC in connection with the recent changes of the Hungarian Companies Act

## Proposals, draft resolutions

Proposals and draft resolutions, relating to the respective items of the agenda of the General Meeting, will be accessible as of January 9, 2013 on the Company's website (www.egis.hu) as well as on www.bet.hu and www.kozzetetelek.hu.

## Way of holding the General Meeting, participation and exercise of voting rights

The share capital of the Company consists of 7,785,715 dematerialized ordinary shares (ISIN: HU0000053947) with the face value of HUF 1,000. Each share represents one vote.

Shareholders are entitled to attend the General Meeting in person or may be represented by proxy. Shareholders have the right to request information within the legal framework provided by law just as to make remarks and proposals, and shareholders holding voting shares have the right to vote. There are no additional conditions regarding the right to request information in the Articles of Association of the Company.

In order to identify owners, the Company initiates a shareholder identification process with the record date of January 23, 2013 in compliance with the General Terms of Central Clearing House and Depository Ltd. (KELER). Closing date and time of the Share Ledger is **on January 28, 2013 at 6 p.m.** Shareholders' rights can be exercised at the General Meeting by those persons who are on record in the Share Ledger at the date and time of closing. In other words, names of shareholders or nominees who intend to exercise their voting right, must be registered in the Share Ledger by this time at the latest.



We kindly call the attention of shareholders that after closing the Share Ledger no application for registration shall be accepted until the day following the conclusion of the General Meeting. Shareholders are kindly requested to take the required measures at their securities account manager/custodian notifying them of intention to vote at the General Meeting, double checking Share Ledger entry and updated identification data. The Company bears no liability for consequences of default or deficiency in fulfilling client related engagements of custodians.

For the sake of smooth administration Shareholders are kindly requested to indicate via telephone or e-mail their intention to attend the AGM, not later than January 28, 2013 by 6.00 p.m. at the Company's Share Office (phone: +36 1 803-5736, e-mail: corpoffice1@egis.hu) Shareholders are also kindly requested to arrive at the venue between 1.00 p.m. and 1.45 p.m. for registration and for picking up the voting device, proving their identity and submitting their documents of authorisation to attend the General Meeting as well as certificate of ownership issued by the securities account manager/custodian.

The closing of Share Ledger shall not deprive persons registered in the Share Ledger of transferring their shares, and transferring shares prior to the General Meeting shall not deprive the persons registered in the Share Ledger of their rights to participate at the General Meeting and to exercise their rights they are entitled to as shareholders.

Shareholders holding at least one per cent of the votes are entitled to request that the Board of Directors put an item on the agenda and can also propose draft resolutions relating to items of the agenda of the General Meeting. Such a request must be submitted in writing within eight days from the day of this announcement, indicating the reason; there are no additional conditions for the exercising of these rights in the Articles of Association of the Company.

Should the General Meeting fail to have a quorum, the General Meeting will be reconvened at the Headquarters of the Company with identical agenda on February 12, 2013 at 2 p.m.

The Board of Directors proposes the General Meeting to determine and pay HUF 240 dividend per share, amounting to 24.00% per nominal value, from the profit of 2011/2012. This amount equals to 10% of the consolidated net profit of the financial year.

Budapest, December 17, 2012

The Board of Directors of Egis Pharmaceuticals PLC